DK0580429T3 - Anvendelse af kompetitive NMDA-receptorantagonister ved behandling af urininkontinens - Google Patents

Anvendelse af kompetitive NMDA-receptorantagonister ved behandling af urininkontinens

Info

Publication number
DK0580429T3
DK0580429T3 DK93305762.2T DK93305762T DK0580429T3 DK 0580429 T3 DK0580429 T3 DK 0580429T3 DK 93305762 T DK93305762 T DK 93305762T DK 0580429 T3 DK0580429 T3 DK 0580429T3
Authority
DK
Denmark
Prior art keywords
urinary incontinence
treatment
receptor antagonists
competitive nmda
nmda receptor
Prior art date
Application number
DK93305762.2T
Other languages
English (en)
Inventor
Karl Bruce Thor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0580429T3 publication Critical patent/DK0580429T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK93305762.2T 1992-07-24 1993-07-22 Anvendelse af kompetitive NMDA-receptorantagonister ved behandling af urininkontinens DK0580429T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/919,480 US5192751A (en) 1992-07-24 1992-07-24 Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Publications (1)

Publication Number Publication Date
DK0580429T3 true DK0580429T3 (da) 1997-07-14

Family

ID=25442169

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93305762.2T DK0580429T3 (da) 1992-07-24 1993-07-22 Anvendelse af kompetitive NMDA-receptorantagonister ved behandling af urininkontinens

Country Status (9)

Country Link
US (1) US5192751A (da)
EP (1) EP0580429B1 (da)
JP (1) JPH06183975A (da)
AT (1) ATE147977T1 (da)
CA (1) CA2100950A1 (da)
DE (1) DE69307617T2 (da)
DK (1) DK0580429T3 (da)
ES (1) ES2096867T3 (da)
GR (1) GR3023032T3 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
PL179448B1 (pl) * 1994-01-31 2000-09-29 Pfizer Neuroochronne zwiazki chromanoloweoraz kompozycje farmaceutyczne zawierajace te zwiazki PL PL PL PL PL
CN1151130C (zh) * 1994-08-18 2004-05-26 辉瑞大药厂 神经保护的3-(哌啶基-1)-苯并二氢吡喃-4,7-二醇和1-(4-氢化苯基)-2-(哌啶基-1)链烷醇衍生物
JP3348230B2 (ja) 1995-03-03 2002-11-20 アルゴス ファーマシューティカル コーポレーション 尿失禁の治療用のデキシトルメトルファン又はデキシトルオルファンの使用
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW427978B (en) * 1996-02-03 2001-04-01 Hoffmann La Roche Tetrahydroisoquinoline derivatives
US5880138A (en) * 1996-10-01 1999-03-09 Eli Lilly And Company NMDA receptor selective antagonists
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
CN1803189B (zh) 1997-07-15 2010-05-26 科罗拉多大学董事会 神经毒素疗法在泌尿系及相关疾病治疗中的应用
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE60035232T2 (de) 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
MX2009014216A (es) * 2007-06-29 2010-07-05 Univ Emory Antagonistas del receptor nmda para neuroproteccion.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
ES2096867T3 (es) 1997-03-16
JPH06183975A (ja) 1994-07-05
CA2100950A1 (en) 1994-01-25
DE69307617T2 (de) 1997-05-28
GR3023032T3 (en) 1997-07-30
DE69307617D1 (de) 1997-03-06
ATE147977T1 (de) 1997-02-15
US5192751A (en) 1993-03-09
EP0580429A1 (en) 1994-01-26
EP0580429B1 (en) 1997-01-22

Similar Documents

Publication Publication Date Title
DK0580429T3 (da) Anvendelse af kompetitive NMDA-receptorantagonister ved behandling af urininkontinens
PT932402E (pt) Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
ATE350060T1 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
ATE154880T1 (de) Multifunktionelle pharmazeutische verbindungen und verfahren zu ihrer verwendung
NL300174I1 (nl) Toepassing van venlafaxine of een aryloxypropaanamineverbinding voor de bereiding van een geneesmiddel voor de behandeling van incontinentie.
FI941396A0 (fi) Koostumuksia biologisesti aktiivisen TGF-valvottua vapauttamista varten
EE04416B1 (et) a1L- agonistide kasutamine uriiniinkontinentsuse raviks
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
BR0002638A (pt) Composições de zinco tópicas e processo de uso
HK1052871A1 (zh) 新城疫病毒的治療用途
DE69223736T2 (de) Acridine-1,8-Dionderivate als therapeutisches Mittel
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
GR3018226T3 (en) Sulfonanilide derivative and medicine.
FI902334A0 (fi) (2R,4S)-2-kloorimetyyli-4-kloori-1-sulfonyylipyrrolidiini-välituotteita, niiden valmistus ja niiden käyttö
SE8303700L (sv) Terapeutisk komposition
EP0467365A3 (en) Use of a 5-hydroxytryptamine-3(5-ht3) receptor antagonist for the preparation of a pharmaceutical composition for treating urinary incontinence
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
ES2053161T3 (es) Composiciones antimicrobianas.
ATE145911T1 (de) Inositol-phosphat-analog als kalzium- antagonistische substanz
WO1992007564A3 (en) Method of treating demyelinating disease
ES2106098T3 (es) Lacidipino para el tratamiento de la arteriosclerosis.
ES2097277T3 (es) Uso de un compuesto ester tiol-s-(2-dietilaminoetilico) para la preparacion de un medicamento para el tratamiento de la incontinencia neuro-muscular.
EP0412941A3 (en) Phospholipids for the treatment of multiple sclerosis